All In Biotech

Drug Trial Radar · NCT07428759

Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years

A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

122

Actual

Start

Mar 10, 2026

Primary completion

Nov 19, 2026

Study completion Nov 19, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months. The study aims to determine if PnMAPS30plus is safe and well-tolerated and whether it helps the body produce antibodies that protect against pneumococcal disease.

Conditions

  • Pneumonia, Bacterial

Interventions

  • Pn-MAPS30plusBiological

    Single dose of Pn-MAPS30plus received intramuscularly.

  • PCV20Combination product

    Single dose of PCV20 received intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Solicited Administration Site Adverse Events (AEs)Time frame: Day 1 to Day 7
  2. Number of Participants with Solicited Systemic AEsTime frame: Day 1 to Day 7
  3. Number of Participants with Unsolicited AEsTime frame: Day 1 to Day 30
  4. Number of Participants with Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 181 (study end)
  5. Number of Participants with Adverse Events of Special Interest (AESIs)Time frame: From Day 1 to Day 181 (study end)
  6. Number of Participants with AEs Leading to withdrawal from the studyTime frame: From Day 1 to Day 181 (study end)
  7. Number of Participants with any Laboratory abnormalitiesTime frame: Day 8 compared to Screening Visit (up to Day -14)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Norwood, South Australia, Australia

  • GSK Investigational Site

    Camberwell, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.